Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...

Xencor (XNCR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most ...

Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been given a consensus rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Seven ...

American Century Companies Inc. raised its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 11.1% during the ...

Xencor, Inc. (NASDAQ:XNCR), a biotechnology company specializing in protein engineering and T cell engager (TCE) technologies, stands at a critical juncture in its development. With a diverse pipeline ...

In a report released today, Peter Lawson from Barclays maintained a Sell rating on Xencor (XNCR – Research Report), with a price target of ...

PASADENA, Calif., March 13, 2025--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases ...

Current written description jurisprudence can make it difficult to obtain broad antibody patents, leading practitioners to explore ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on XNCR: Xencor NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Xencor, Inc. (NASDAQ:XNCR), a biotechnology company specializing in protein engineering and T cell engager (TCE) technologies, stands at a critical juncture in its development. With a diverse ...

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary ...